Bausch Health Companies Inc(BHC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.96 | Insider Own | 11.4% | Shs Outstand | 373.9M | Perf Week | -11.13% |
| Market Cap | 2.27B | Forward P/E | 1.4 | EPS next Y | -4.6% | Insider Trans | -0.14% | Shs Float | 331.4M | Perf Month | -2.72% |
| Enterprise Value | 22.18B | PEG | - | EPS next Q | 1.26 | Inst Own | 67.97% | Short Float | 2.54% | Perf Quarter | 17.86% |
| Income | -1.10B | P/S | 0.21 | EPS this Y | 18.43% | Inst Trans | 1.8% | Short Ratio | 2.36 | Perf Half Y | 11.79% |
| Sales | 10.85B | P/B | - | EPS next 5Y | -4.26% | ROA | -4.22% | Short Interest | 8.42M | Perf YTD | -12.66% |
| Book/sh | -4.74 | P/C | 1.24 | EPS past 3/5Y | - | ROE | - | 52W High | -24.12% ($8.00) | Perf Year | -15.1% |
| Cash/sh | 4.91 | P/FCF | 1.6 | Sales past 3/5Y | 8.11% 5.04% | ROIC | -6.06% | 52W Low | 40.18% ($4.33) | Perf 3Y | -29.75% |
| Dividend Est. | - | EV/EBITDA | 5.68 | EPS Y/Y TTM | -1216.28% | Gross Margin | 63.02% | Volatility(W/M) | 4.69% 4.62% | Perf 5Y | -78.66% |
| Dividend TTM | - | EV/Sales | 2.04 | Sales Y/Y TTM | 10.09% | Oper. Margin | 25.17% | ATR (14) | 0.32 | Perf 10Y | -78.37% |
| Dividend Ex-Date | 2010/11/10 | Quick Ratio | 1.08 | EPS Q/Q | 72.02% | Profit Margin | -10.12% | RSI (14) | 45.31 | Recom | 2.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.44 | Sales Q/Q | 12.73% | SMA20 | -7.11% ($6.53) | Beta | 0.37 | Target Price | $7.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/7/29 | SMA50 | 5.09% ($5.78) | Rel Volume | 0.44 | Prev Close | $6.16 |
| Employees | 20300 | LT Debt/Eq | - | EPS/Sales Surpr. | 25.12% 7.26% | SMA200 | 3.63% ($5.86) | Avg Volume(3M) | 3.56M | Price | $6.07 |
| IPO | 1994/3/29 | Option/Short | Yes/Yes | Trades | 5433 | Volume | 1,571,376 | Change | -1.46% |
Company
BHC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This is a global pharmaceutical company that develops and sells a wide range of specialty medicines. It markets both specialty and general pharmaceuticals across multiple therapeutic areas, including gastrointestinal, dermatology, and neurology, and also holds a stake in an ophthalmology healthcare subsidiary. As a specialty pharmaceutical player with a diversified drug portfolio and a global business foundation, debt management is a key challenge for the stock.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
BHC has weak earning power
25.17% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +18.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -29.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 68.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IBHL 0.03%
HYHG 0.02%
XB 0.01%
EVHY 0.01%
MYHB 0.01%It ranks #4 in the industry
Based on market cap of $2B.
BHC $2B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is BHC?
BHC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BHC?
The market cap of BHC is approximately $2.3B, ranking 1,989 within its sector.
What is the 52-week high and low for BHC?
BHC has recorded a 52-week high of $8.00 and a low of $4.33.
